Literature DB >> 1744061

A 102-center prospective study of seizure in association with bupropion.

J A Johnston1, C G Lineberry, J A Ascher, J Davidson, M A Khayrallah, J P Feighner, P Stark.   

Abstract

BACKGROUND: This trial was conducted to determine the incidence of seizures associated with the use of bupropion.
METHOD: A total of 3341 depressed patients from 102 sites were enrolled in this 8-week, prospective, open trial. Following the 8-week treatment phase, patients could elect to enroll in a humanitarian continuation phase of unlimited duration. Dosing was initiated at 225 mg/day and increased to 450 mg/day as tolerated. Investigators carefully monitored seizure occurrences and rated their patients' response to and tolerance of bupropion.
RESULTS: A total of 1986 patients (61%) completed the 8-week treatment phase, and 1616 (81%) of these elected to be maintained on bupropion treatment in the humanitarian continuation phase. The observed seizure rate was 0.24% for the treatment phase and 0.40% for the entire study. An 8-week survival analysis performed on patients with a dosing regimen of 300 to 450 mg/day yielded a cumulative rate of 0.36%. Patients, including those previously resistant to antidepressant treatment, responded to and tolerated bupropion well.
CONCLUSION: These rates confirm earlier seizure estimates and fall within accepted parameters for antidepressant drugs. This trial enhances bupropion's position as a valuable alternative for the management of depression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1744061

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  27 in total

1.  Acute hepatitis induced by bupropion.

Authors:  K Q Hu; L Tiyyagura; G Kanel; A G Redeker
Journal:  Dig Dis Sci       Date:  2000-09       Impact factor: 3.199

2.  Depression in Individuals with Epilepsy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-11       Impact factor: 3.598

Review 3.  Tobacco addiction and the dysregulation of brain stress systems.

Authors:  Adrie W Bruijnzeel
Journal:  Neurosci Biobehav Rev       Date:  2012-03-03       Impact factor: 8.989

Review 4.  Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Authors:  Linda P Dwoskin; Anthony S Rauhut; Kelley A King-Pospisil; Michael T Bardo
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

5.  A case report of seizure induced by bupropion nasal insufflation.

Authors:  Stanley Hill; Harminder Sikand; Jonathan Lee
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 6.  Bupropion: a review of its use in the management of smoking cessation.

Authors:  K J Holm; C M Spencer
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

7.  Current Perspectives on the Diagnosis and Treatment of Double Depression.

Authors:  D J Hellerstein; S A Little
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

Review 8.  Drug therapy for geriatric depression.

Authors:  R Bressler; M D Katz
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

9.  Serious adverse reactions of bupropion for smoking cessation: analysis of the French Pharmacovigilance Database from 2001 to 2004.

Authors:  Marie-Nöelle Beyens; Claire Guy; Genevieve Mounier; Sylvie Laporte; Michel Ollagnier
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 10.  Spotlight on bupropion in major depressive disorder.

Authors:  Sohita Dhillon; Lily P H Yang; Monique P Curran
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.